CONVINCE试验6个月中期分析:多数患者可达高剂量血液透析滤过对流剂量
CONVINCE随机对照试验将653例终末期肾病患者1:1随机分配至高剂量血液透析滤过(HDF)或继续高通量血液透析,评估基线、第3个月和第6个月每次治疗对流剂量≥23 L(±1 L)的达标比例。结果显示83%患者三次访视均达标,仅糖尿病与达标情况存在差异,高剂量HDF对几乎所有患者可行且可维持6个月。
要点
- 83%患者三次访视均达对流剂量≥23 L目标
- 仅11%患者一次未达标,4%两次未达标,2%三次未达标
- 除糖尿病外,达标与未达标患者特征无显著差异
核心结论
- 在CONVINCE试验中,高剂量HDF对几乎所有患者可行,并可在6个月随访期间维持。
- 除糖尿病外,多变量分析未发现其他指征混杂迹象可解释高剂量HDF可能的生存获益。
研究设计与样本
- CONVINCE为随机对照试验,将终末期肾病患者1:1随机分配至高剂量HDF组或继续高通量血液透析组。
- 本分析纳入653例随机分配至HDF组的患者,平均年龄62.2岁(SD 13.5),36%为女性,81%使用动静脉瘘,33%有糖尿病。
- 评估基线、第3个月和第6个月每次治疗对流剂量≥23 L(范围±1 L)的达标比例。
主要发现
- 三次访视中,分别有75例(11%)、27例(4%)、11例(2%)患者一次、两次、三次未达对流剂量目标。
- 83%患者三次访视均达标,17%患者至少一次未达标,6%患者至少两次未达标。
- 除糖尿病外,始终达标患者与未达标患者在患者特征上无显著差异。
关键数值与推荐
- 高剂量HDF目标定义为每次治疗对流剂量≥23 L(范围±1 L)。
临床怎么用
- 高剂量HDF对流剂量目标在多数终末期肾病患者中可实现并维持6个月。
- 糖尿病可能是影响对流剂量达标的因素之一。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: High convection volumes in hemodiafiltration (HDF) result in improved survival; however, it remains unclear whether it is achievable in all patients. METHODS: CONVINCE, a randomized controlled trial, randomized patients with end-stage kidney disease 1:1 to high-dose HDF versus high-flux hemodialysis (HD) continuation. We evaluated the proportion of patients achieving high-dose HDF target: convection volume per visit of ≥23 l (range ±1 l) at baseline, month 3, and month 6. We compared baseline characteristics in the following 2 ways: (i) patients on target for all 3 visits versus patients who missed target on ≥1 visits and (ii) patients on target for all 3 visits or missing it once versus patients who missed target on ≥2 visits. RESULTS: A total of 653 patients were randomized to HDF. Their mean age was 62.2 (SD 13.5) years, 36% were female, 81% had fistula vascular access, and 33% had diabetes. Across the 3 visits, 75 patients (11%), 27 patients (4%), and 11 patients (2%) missed the convection volume target once, twice, and thrice, respectively. Apart from diabetes, there were no apparent differences in patient characteristics between patients who always achieved the high-dose target (83%) and those who missed the target either once or more (17%) or twice or more (6%). CONCLUSION: Achieving high-dose HDF is feasible for nearly all patients in CONVINCE and could be maintained during the 6-month follow-up period. Apart from diabetes, there were no other indications for confounding by indication on multivariable analyses that may explain the potential survival advantage for patients receiving high-dose HDF.
引用
- Vernooij RWM, Hockham C, Barth C, et al. High-Target Hemodiafiltration Convective Dose Achieved in Most Patients in a 6-Month Intermediary Analysis of the CONVINCE Randomized Controlled Trial. Kidney Int Rep. 2023. PMID: 38025213. doi:10.1016/j.ekir.2023.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。